Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/29/2024 (updated 4/4/2024)
This session offered a review of the programmatic work of the Foundation for Opioid Response Efforts (FORE), discussed different types of funding opportunities, and then used FORE’s application process as an example of applying for and receiving funding from private foundations.
Posted 3/28/2024 (updated 4/4/2024)
This session outlined how the Communities of Practice for Rural Communities Opioid Response Program (COP-RCORP) Consortium created a Disparities Impact Statement (DIS) that encompassed four Ohio counties (Ashtabula, Fairfield, Sandusky, and Seneca) and three HRSA grants (two RCORP-Psychostimulant grants and one RCORP-Behavioral Health Support grant).
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Archives Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 2:45 PM
Posted 1/19/2024 (updated 3/28/2024)
The FDA announced that the manufacturer of NARCAN 4 mg Nasal Spray products, Emergent BioSolutions, has extended the shelf-life of their product from 3 years to 4 years. This new extension of shelf-life was requested by the FDA to help prevent overdoses and reduce overdose-related deaths.
RSV 2023 Session: Quick Response Teams: Preventing Deaths While Sharing the Hope of Recovery (Day 1)
Posted 7/26/2023 (updated 3/28/2024)
The presentation discussed the development and changes in the utilization of a Quick Response Team in an Ohio rural community.
Posted 6/8/2022 (updated 3/27/2024)
Posted 6/7/2022 (updated 3/27/2024)
This session provided information on program updates and the Year 2 Sustainability template due September 2022.
Posted 6/7/2022 (updated 3/27/2024)
This session began with a discussion of the timeline, PIMS, sustainability plan, and no cost extensions with the Implementation I cohort. The Implementation II cohort joined the discussion and information was provided on sustaining change in communities.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.